Drug Profile
Regorafenib - Bayer Healthcare
Alternative Names: BAY-734506; fluoro-sorafenib; Resihance; StivargaLatest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer ARCAGY/GINECO Group; Bayer HealthCare; Bayer Zydus Pharma; Bristol-Myers Squibb; British Columbia Cancer Agency; Global Coalition for Adaptive Research; Jiangsu Hengrui Medicine Co.; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Ono Pharmaceutical; Spanish Cooperative Group for Digestive Tumour Therapy; University of Pittsburgh
- Class Amides; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenylurea compounds; Pyridines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Mitogen-activated-protein kinase 11-inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; TrkA receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Gastrointestinal stromal tumours; Liver cancer
- Phase III Glioblastoma
- Phase II Adenoid cystic carcinoma; Biliary cancer; Cholangiocarcinoma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- No development reported Acute myeloid leukaemia; Rhabdomyosarcoma
- Discontinued Non-small cell lung cancer; Wet age-related macular degeneration
Most Recent Events
- 24 Jan 2024 Phase-II clinical trials in Solid tumours in South Korea (PO) (NCT06246643)
- 20 Oct 2023 Efficacy and adverse events data from phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 30 Apr 2023 Translational Research in Oncology in collaboration with Bayer and Novartis withdrew a phase II REFIT-MSS trial due to sponsor decision not to proceed further (Combination therapy, Second line or greater, Late stage) in Solid tumours (PO) (NCT05582031)